European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.
Related Articles
Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs
Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
The Democrats Show Why They Lost
At a meeting of the DNC, the party seemed to be at pains to demonstrate that it learned nothing from its 2024 defeat. February 02,…
AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer
Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.
Meet Maria Miranda – The Heartbeat of Patient Advocacy
Maria is more than a patient advocate she is a guardian of comfort and a champion of care
The Power & Reach of Social Media for Reliable Patient… : Oncology Times
An abstract is unavailable.
Navigating Refractory RCC: Insights from the TiNivo-2 Trial
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on sequencing targeted therapies.
IMM-1-104 Plus Chemo Generates Responses in First-Line Pancreatic Cancer
First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.
Mobile Lung Screening
Moffitt is taking lung screenings on the road with our new mobile low-dose CT scan, ensuring easy access for eligible individuals in Florida.
How to stay active when you don’t feel your best
It can be difficult to stay active, especially when you aren’t feeling your best. Here, our experts share seven tips for balancing activity and rest…
Evolutionary cell biologist Dr. Grant King named a Hanna Gray Fellow
The Howard Hughes Medical Institute has named Fred Hutch Cancer Center postdoctoral researcher Grant King, PhD, a Hanna H. Gray Fellow — investing up to…
